Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5934647 | 1.00 | MEN1 (0.41) | MEN1MAPK1KMT2ACA12CA14 | |
| SCHEMBL14416213 | 1.00 | MEN1 (0.41) | MEN1MAPK1KMT2ACA12CA14 | |
| SCHEMBL1980398 | 0.93 | MEN1 (0.43) | MEN1MAPK1KMT2ACA12CA14 | |
| SCHEMBL6566948 | 0.88 | MEN1 (0.38) | MEN1MAPK1KMT2ACA12CA14 | |
| SCHEMBL30894058 | 0.85 | MEN1 (0.40) | MEN1MAPK1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL7935586 | 0.85 | MEN1 (0.40) | MEN1MAPK1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL31527127 | 0.85 | MEN1 (0.42) | MEN1MAPK1KMT2ACA12CA14 | |
| SCHEMBL298008 | 0.84 | KMT2A (0.38) | MEN1MAPK1KMT2ACA12CA14 | |
| SCHEMBL13525930 | 0.84 | KMT2A (0.38) | MEN1MAPK1KMT2ACA12CA14 | |
| SCHEMBL10040060 | 0.84 | KMT2A (0.38) | MEN1MAPK1KMT2ACA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3927698-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-12-29 | — | — | EP | disclosed |
| US-20200268730-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-27 | — | — | US | disclosed |
| US-20200268730-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-27 | — | — | US | disclosed |
| US-7264792-B2 | Solid phase preparation of 18F-labelled amino acids | GE HEALTHCARE LIMITED (GB) | 2007-09-04 | — | — | US | disclosed |
| US-7264792-B2 | Solid phase preparation of 18F-labelled amino acids | GE HEALTHCARE LIMITED (GB) | 2007-09-04 | — | — | US | disclosed |
| EP-1572601-B1 | SOLID-PHASE PREPARATION OF 18 F-LABELLED AMINO ACIDS | GE HEALTHCARE LTD (GB) | 2007-08-15 | — | — | EP | disclosed |
| US-20060039855-A1 | Solid phase preparation of 18f-labelled amino acids | GE HEALTHCARE LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1572601-A1 | SOLID-PHASE PREPARATION OF 18 F-LABELLED AMINO ACIDS | GE Healthcare Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056725-A1 | SOLID-PHASE PREPARATION OF 18F-LABELLED AMINO ACIDS | GE HEALTHCARE LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| EP-0862464-A4 | AMINO ACID ANALOGS FOR TUMOR IMAGING | UNIV EMORY (US) | 2001-07-25 | — | — | EP | disclosed |
| US-5817776-A | TECHNETIUM 99 COMPLEXES, SINGLE PHOTON EMISSION TOMOGRAPHY | EMORY UNIVERSITY (US) | 1998-10-06 | — | — | US | disclosed |
| US-5808146-A | Amino acid analogs for tumor imaging | EMORY UNIVERSITY (US) | 1998-09-15 | — | — | US | disclosed |
| EP-0862464-A1 | AMINO ACID ANALOGS FOR TUMOR IMAGING | EMORY UNIVERSITY (US) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997017092-A1 | AMINO ACID ANALOGS FOR TUMOR IMAGING | EMORY UNIVERSITY (US) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268730-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | HDGF, FABP1, NR1H4 | MEN1 4681/4885MAPK1 3282/4885KMT2A 2809/4885 |
| US-20060039855-A1 | Solid phase preparation of 18f-labelled amino acids | SLC7A5, SLC43A1, SLCO2B1 | MEN1 1141/4885MAPK1 2305/4885KMT2A 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.